PET-16

• Description :

  PET-16 is a selective HSP70 inhibitor that binds to an allosteric pocket of the substrate-binding domain. PET-16 inhibits the ability of HSP70 to cycle between ATP-bound and ADP-bound states. PET-16 induces apoptosis in multiple myeloma[1].

• CAS Number :

  [34387-64-9]

• UNSPSC :

  12352005

• Hazard Statement :

  H315-H319-H335

• Target :

  Apoptosis; HSP

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/pet-16.html

• Smiles :

  C1(C#C[P+](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4)=CC=CC=C1.[Br-]

• Molecular Formula :

  C26H20BrP

• Molecular Weight :

  443.31

• Precautions :

  P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P362+P364-P403+P233-P405-P501

• References & Citations :

  [1]Charvann K Bailey, et al. Efficacy of the HSP70 inhibitor PET-16 in multiple myeloma. Cancer Biol Ther. 2015;16 (9) :1422-6. |[2]Anna Budina-Kolomets, et al. HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors. Cancer Res. 2016 May 1;76 (9) :2720-30.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported